Mira Pharmaceuticals (MIRA) Receivables - Other (2023 - 2025)

Mira Pharmaceuticals (MIRA) posted Receivables - Other of $35439.0 for Q4 2025, little changed sequentially from $35439.0 in Q3 2025.

Mira Pharmaceuticals (MIRA) Receivables - Other (2023 - 2025) Analysis & Trends

Mira Pharmaceuticals has reported Receivables - Other for 3 years, with the latest figure at $35439.0 in Q4 2025.

Quarterly Receivables - Other changed N/A year-over-year to $35439.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35439.0 (changed N/A YoY) and the FY2025 annual result came in at $35439.0, changed 0.0% from the prior year.
Receivables - Other held at $35439.0 in Q4 2025 per MIRA's latest filing, from $35439.0 in the prior quarter.
Over five years, Receivables - Other peaked at $93487.0 in Q1 2024 and troughed at $11862.0 in Q4 2023.
A 3-year average of $41566.6 and a median of $37719.5 in 2024 frame the typical range for Receivables - Other.
The widest YoY moves for Receivables - Other: up 66.67% in 2025, down 57.21% in 2025.
Over 3 years, Receivables - Other stood at $11862.0 in 2023, then jumped by 198.76% to $35439.0 in 2024, then changed by 0.0% to $35439.0 in 2025.
According to Business Quant data, Receivables - Other over the past three periods registered $35439.0, $35439.0, and $40000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Mira Pharmaceuticals	18.47 Mn	7.44 Mn	-

Download Data